241 related articles for article (PubMed ID: 33914864)
21. Therapeutic drug concentrations of isavuconazole following the administration of isavuconazonium sulfate capsules via gastro-jejunum tube: A case report.
Adamsick ML; Elshaboury RH; Gift T; Mansour MK; Kotton CN; Gandhi RG
Transpl Infect Dis; 2019 Apr; 21(2):e13048. PubMed ID: 30636363
[TBL] [Abstract][Full Text] [Related]
22. Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.
McCarthy MW; Moriyama B; Petraitiene R; Walsh TJ; Petraitis V
Clin Pharmacokinet; 2018 Dec; 57(12):1483-1491. PubMed ID: 29725999
[TBL] [Abstract][Full Text] [Related]
23. Isavuconazole for the Treatment of Invasive Mold Disease in Solid Organ Transplant Recipients: A Multicenter Study on Efficacy and Safety in Real-life Clinical Practice.
Fernández-Ruiz M; Bodro M; Gutiérrez Martín I; Rodriguez-Álvarez R; Ruiz-Ruigómez M; Sabé N; López-Viñau T; Valerio M; Illaro A; Fortún J; Salto-Alejandre S; Cordero E; Fariñas MDC; Muñoz P; Vidal E; Carratalà J; Goikoetxea J; Ramos-Martínez A; Moreno A; Aguado JM;
Transplantation; 2023 Mar; 107(3):762-773. PubMed ID: 36367924
[TBL] [Abstract][Full Text] [Related]
24. Clinical experience with isavuconazole in healthy volunteers and patients with invasive aspergillosis in China, and the results from an exposure-response analysis.
Zhang J; Zhang Y; Wu D; Cao G; Hamed K; Desai A; Aram JA; Guo X; Fayyad R; Cornely OA
Mycoses; 2021 Apr; 64(4):445-456. PubMed ID: 33355949
[TBL] [Abstract][Full Text] [Related]
25. Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis.
Cheng MP; Orejas JL; Arbona-Haddad E; Bold TD; Solomon IH; Chen K; Pandit A; Kusztos AE; Cummins KC; Liakos A; Marty FM; Koo S; Hammond SP
Mycoses; 2020 Jan; 63(1):58-64. PubMed ID: 31587405
[TBL] [Abstract][Full Text] [Related]
26. Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.
Murrell D; Bossaer JB; Carico R; Harirforoosh S; Cluck D
Int J Pharm Pract; 2017 Feb; 25(1):18-30. PubMed ID: 27569742
[TBL] [Abstract][Full Text] [Related]
27. Isavuconazole As Successful Salvage Therapy for Mucormycosis in Pediatric Patients.
Ashkenazi-Hoffnung L; Bilavsky E; Levy I; Grisaru G; Sadot E; Ben-Ami R; Novikov A; Fischer S; Nahum E; Scheuerman O
Pediatr Infect Dis J; 2020 Aug; 39(8):718-724. PubMed ID: 32251256
[TBL] [Abstract][Full Text] [Related]
28. Isavuconazole use and TDM in real-world pediatric practice.
Fernández Ledesma B; Mendoza-Palomar N; Melendo Pérez S; Fernández-Polo A; Renedo Miró B; Pau Parra A; Luque Pardos S; Grau Cerrato S; Vima Bofarull J; Martín-Gómez MT; Pujol Jover M; Benítez-Carbante MI; Díaz de Heredia C; Soler-Palacin P
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0082923. PubMed ID: 37962334
[TBL] [Abstract][Full Text] [Related]
29. Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi.
Desai A; Kovanda L; Kowalski D; Lu Q; Townsend R; Bonate PL
Antimicrob Agents Chemother; 2016 Sep; 60(9):5483-91. PubMed ID: 27381396
[TBL] [Abstract][Full Text] [Related]
30. Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies.
Hamed K; Engelhardt M; Kovanda LL; Huang JJ; Yan J; Aram JA
Sci Rep; 2023 Apr; 13(1):6730. PubMed ID: 37185921
[TBL] [Abstract][Full Text] [Related]
31. The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom.
Floros L; Pagliuca A; Taie AA; Weidlich D; Rita Capparella M; Georgallis M; Sung AH
J Med Econ; 2020 Jan; 23(1):86-97. PubMed ID: 31262225
[No Abstract] [Full Text] [Related]
32. Successful isavuconazole salvage therapy in a patient with invasive mucormycosis.
Ervens J; Ghannoum M; Graf B; Schwartz S
Infection; 2014 Apr; 42(2):429-32. PubMed ID: 24217961
[TBL] [Abstract][Full Text] [Related]
33. Safety and effectiveness of isavuconazole in real-life non-neutropenic patients.
Monzó-Gallo P; Lopera C; Badía-Tejero AM; Machado M; García-Rodríguez J; Vidal-Cortés P; Merino E; Calderón J; Fortún J; Palacios-Baena ZR; Pemán J; Sanchis JR; Aguilar-Guisado M; Gudiol C; Ramos JC; Sánchez-Romero I; Martin-Davila P; López-Cortés LE; Salavert M; Ruiz-Camps I; Chumbita M; Aiello TF; Peyrony O; Puerta-Alcalde P; Soriano A; Marco F; Garcia-Vidal C
Int J Infect Dis; 2024 Jul; 144():107070. PubMed ID: 38663477
[TBL] [Abstract][Full Text] [Related]
34. Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.
Rybak JM; Marx KR; Nishimoto AT; Rogers PD
Pharmacotherapy; 2015 Nov; 35(11):1037-51. PubMed ID: 26598096
[TBL] [Abstract][Full Text] [Related]
35. The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain.
Azanza JR; Grau S; Vázquez L; Rebollo P; Peral C; López-Ibáñez de Aldecoa A; López-Gómez V
Mycoses; 2021 Jan; 64(1):66-77. PubMed ID: 32989796
[TBL] [Abstract][Full Text] [Related]
36. Successful treatment of invasive mucormycosis with isavuconazole in pediatric patients.
Barg AA; Malkiel S; Bartuv M; Greenberg G; Toren A; Keller N
Pediatr Blood Cancer; 2018 Oct; 65(10):e27281. PubMed ID: 29932282
[TBL] [Abstract][Full Text] [Related]
37. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
Maertens JA; Raad II; Marr KA; Patterson TF; Kontoyiannis DP; Cornely OA; Bow EJ; Rahav G; Neofytos D; Aoun M; Baddley JW; Giladi M; Heinz WJ; Herbrecht R; Hope W; Karthaus M; Lee DG; Lortholary O; Morrison VA; Oren I; Selleslag D; Shoham S; Thompson GR; Lee M; Maher RM; Schmitt-Hoffmann AH; Zeiher B; Ullmann AJ
Lancet; 2016 Feb; 387(10020):760-9. PubMed ID: 26684607
[TBL] [Abstract][Full Text] [Related]
38. Treatment Failure of Isavuconazole in a Patient with Cryptococcosis.
Linder KA; Gandhi TN; Miceli MH
Mycopathologia; 2019 Oct; 184(5):667-670. PubMed ID: 31451965
[TBL] [Abstract][Full Text] [Related]
39. A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.
Wilby KJ
Eur J Drug Metab Pharmacokinet; 2018 Jun; 43(3):281-290. PubMed ID: 29101732
[TBL] [Abstract][Full Text] [Related]
40. Isavuconazole: a new extended spectrum triazole for invasive mold diseases.
Ananda-Rajah MR; Kontoyiannis D
Future Microbiol; 2015; 10(5):693-708. PubMed ID: 26000646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
